Siemens' DPC (Diagnostic Products Corporation) buy gets German OK:
This article was originally published in Clinica
Siemens' proposed acquisition of Los Angeles, California-based immunodiagnostics company Diagnostic Products Corporation (DPC) has received clearance from German antitrust authorities. The news comes shy of a week after the US Federal Trade Commission gave the go-ahead to the $1.86bn transaction (see Clinica No 1211, p 14). The companies still require shareholder approval before closing the acquisition.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.